| Title |
Association between β-blocker use and mortality in critically ill patients: a nested cohort study
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, May 2018
|
| DOI | 10.1186/s40360-018-0213-6 |
| Pubmed ID | |
| Authors |
Shmeylan A. Al Harbi, Khalid A. Al Sulaiman, Hani Tamim, Hasan M. Al-Dorzi, Musharaf Sadat, Yaseen Arabi |
| Abstract |
β-blockers have several indications in critically ill patients and are commonly used. The aim of this study is to examine the relationship between the use of β-blockers in critically ill patients and mortality. This was a nested cohort study in which all medical-surgical ICU patients (N = 523) enrolled in a randomized clinical trial of intensive insulin therapy (ISRCTN07413772) were grouped according to β-blocker use during ICU stay. To account for the indication of β-blockers, we constructed a propensity score using selected clinically-relevant and statistically-significant variables related to β-blocker exposure and outcome. The primary endpoints were all-cause ICU and hospital mortality. Secondary endpoints were the development of severe sepsis during ICU stay, ICU and hospital length of stay, and mechanical ventilation duration. Using multivariable models, we adjusted the associations of β-blockers and these outcomes to the propensity score. Of the 523 patients enrolled in the study, 89 (17.0%) received β-blockers during their ICU stay. There were no significant associations between β-blocker therapy and ICU mortality (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 0.83-2.9, P = 0.16), hospital mortality (aOR 1.09, 95% CI 0.99-1.20, P = 0.73), the risk of ICU-acquired severe sepsis (aOR 1.67, 95% CI 0.95-2.97, P = 0.08), mechanical ventilation duration (P = 0.17), or ICU length of stay (P = 0.22). However, β-blocker use was associated with increased ICU and hospital mortality among nondiabetic patients (aOR 2.93, 95% CI 1.19-7.23, and 2.43, 95% CI 1.05-5.64, respectively). Our study showed that β-blockers during the ICU stay had no significant association with mortality or morbidity. However, β-blocker therapy was associated with increased mortality in non-diabetic patients. ISRCTN07413772 ; (dated 13.07.2005). |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 8 | 44% |
| Italy | 1 | 6% |
| United States | 1 | 6% |
| Oman | 1 | 6% |
| Unknown | 7 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 72% |
| Scientists | 3 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 19% |
| Student > Bachelor | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 2 | 6% |
| Student > Master | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 17 | 47% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Engineering | 2 | 6% |
| Social Sciences | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 17 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2020.
All research outputs
#2,375,014
of 24,749,767 outputs
Outputs from BMC Pharmacology and Toxicology
#36
of 471 outputs
Outputs of similar age
#48,580
of 333,348 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#4
of 11 outputs
Altmetric has tracked 24,749,767 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,348 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.